SEC Filing Summary: StemCells, Inc. (Form 10-K)
Business Context and Reporting Period
Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Period: Fiscal year ended December 31, 2007
Business Overview: StemCells, Inc. is a biopharmaceutical company developing cell-based therapeutics to treat damage or degeneration of major organ systems. The company focuses on two primary programs: the CNS Program (human neural stem cells) and the Liver Program (human liver engrafting cells). The company has no approved products and has incurred operating losses since inception.
Key Financial Metrics (Year Ended Dec 31, 2007)
| Metric | 2007 | 2006 |
|---|---|---|
| Revenue (Licensing & Grants) | $56,722 | $92,850 |
| Net Loss | $(25,022,802) | $(18,948,380) |
| Loss Per Share (Basic & Diluted) | $(0.31) | $(0.25) |
| Research & Development Expenses | $19,937,426 | $13,600,433 |
| General & Administrative Expenses | $7,927,443 | $7,154,042 |
| Wind-down Expenses (Rhode Island facility) | $783,022 | $709,209 |
| Cash & Cash Equivalents (End of Period) | $9,759,169 | $51,795,529 |
| Marketable Securities (Total) | $29,847,384 | $7,266,278 |
| Total Assets | $48,282,566 | $66,856,817 |
| Long-term Debt (Bonds & Capital Leases) | $1,034,435 | $1,145,416 |
| Accrued Wind-down Expenses (Liability) | $6,143,000 | $6,750,000 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 39% to $57,000 from $93,000 in 2006, primarily due to the completion of a $464,000 Small Business Technology Transfer Grant in 2006.
- Increased Operating Loss: Net loss increased by approximately $6.1 million (32%) to $25.0 million, driven by a 47% increase in R&D expenses ($6.3 million increase) and an 11% increase in G&A expenses.
- Cash Position: Cash and cash equivalents decreased significantly by $42.0 million (81%) to $9.8 million. This was primarily due to a redeployment of cash into marketable debt securities (investing activities) and increased cash burn from operations ($20.9 million used).
- Other Income: Other income increased to $3.6 million from $2.4 million, largely due to a $716,000 realized gain on the sale of ReNeuron shares and $550,000 in income from the ReNeuron license agreement.
Guidance, Outlook, Risks, and Unusual Items
- Clinical Progress: The company completed enrollment and dosing of a six-patient Phase I clinical trial for HuCNS-SC (human neural stem cells) to treat Neuronal Ceroid Lipofuscinosis (NCL/Batten disease). Completion is expected in early 2009. Preclinical work continues for spinal cord injury, myelin disorders, and retinal disorders.
- Liquidity Risk: Management states that existing capital resources may not be sufficient to fund operations beyond the next 12 to 18 months. The company must obtain significant additional capital to sustain R&D and operations.
- Wind-down Liability: The company maintains a reserve of $6.14 million for lease and operating costs associated with its former Rhode Island facility, which it vacated in 1999 but remains obligated to pay through June 2013. This liability is a significant drain on cash resources.
- Legal Proceedings: The company is involved in patent litigation against Neuralstem, Inc. The litigation is currently stayed pending reexamination of patents by the U.S. Patent and Trademark Office.
- Acquisition Attempt: In December 2007, the company lent $1.0 million to Progenitor Cell Therapy, LLC (PCT) in connection with a potential acquisition. Discussions were terminated in March 2008; the loan is expected to be repaid.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to raise capital given the explicit statement that cash reserves may only last 12-18 months.
- Rhode Island Liability: Confirm the status of subleasing the former Rhode Island facility, as the $6.1 million reserve and ongoing cash outflows depend on occupancy rates and market conditions.
- Clinical Trial Results: Monitor the safety and efficacy data from the Phase I NCL trial, expected in early 2009, as the company's future is heavily dependent on this single product candidate.
- Patent Litigation: Track the outcome of the PTO reexamination of patents involved in the Neuralstem lawsuit, as this impacts the company's intellectual property portfolio.
- ReNeuron Investment: Review the valuation and liquidity of the remaining ReNeuron Group plc shares (approx. 4.8 million shares), which are subject to foreign exchange and market price volatility.